From owner-btk-mca@hgmp.mrc.ac.uk Thu May 18 18:50:33 2000 Return-Path: Received: by mercury.hgmp.mrc.ac.uk (Postfix, from userid 110) id 6A07017A4E; Thu, 18 May 2000 18:50:28 +0100 (BST) Received: from niobium.hgmp.mrc.ac.uk (niobium [193.62.192.41]) by hgmp.mrc.ac.uk (8.9.3/8.9.3) with ESMTP id SAA13748; Thu, 18 May 2000 18:50:23 +0100 (BST) Received: (from news@localhost) by niobium.hgmp.mrc.ac.uk (8.9.3+Sun/8.8.8) id SAA14080; Thu, 18 May 2000 18:50:21 +0100 (BST) X-Authentication-Warning: niobium.hgmp.mrc.ac.uk: news set sender to using -f From: Petr Kuzmic X-Newsgroups: bionet.general,bionet.metabolic-reg,bionet.software,bionet.molbio.methds-reagnts,sci.med.diseases.hepatitis Subject: [ANN] Preprints - Hepatitis C viral dynamics Date: Thu, 18 May 2000 12:47:13 -0500 Organization: BioKin Ltd. [http://www.biokin.com] Lines: 48 Message-ID: <39242CA1.56D4594C@biokin.com> Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit X-Trace: news.chorus.net 958671878 23625 216.165.147.26 (18 May 2000 17:44:38 GMT) X-Complaints-To: abuse@chorus.net X-Mailer: Mozilla 4.72 [en] (WinNT; U) X-Accept-Language: en To: bio-software@hgmp.mrc.ac.uk, bioforum@hgmp.mrc.ac.uk, btk-mca@hgmp.mrc.ac.uk, methods@hgmp.mrc.ac.uk Sender: owner-btk-mca@hgmp.mrc.ac.uk Precedence: bulk We have been doing some mathematical modeling of changes over time in 1. hepatitis-C virus (HCV) load, 2. HLA-1 beta-2-microglobulin titer, and 3. alanine tranferase activity upon treatment of HCV-positive individuals with Interferon, with or without Ribavirin ("combination therapy"). Partial results of these studies will be presented at the "Digestive Disease Week" annual conference in San Diego [ http://www.ddw.org ], starting this Monday (May 25th). The purpose of this announcement is to draw interested people to electronic preprints of several posters that will be presented at the meeting. Here they are: ----- "Dynamics of HLA-1 beta-2-Microglobulin subunit during treatment with high dose Interferon with or without Ribavirin: correlation with serum HCV RNA and ALT" Lake-Bakaar, G.; Ruffini, L.; and Kuzmic, P. (2000) Digest. Dis. Week , San Diego, May 22-25, 2000. [ http://www.biokin.com/virafit/papers/ddw105411.html ] ----- "Dynamics of HLA-1 beta-2-Microglobulin subunit during treatment with high dose Interferon with or without Ribavirin: correlation with serum HCV RNA and ALT" Lake-Bakaar, G.; Ruffini, L.; and Kuzmic, P. (2000) Digest. Dis. Week , San Diego, May 22-25, 2000. [http://www.biokin.com/virafit/papers/ddw105418.html] ----- "Early HCV RNA 'rebound' during daily high dose Interferon treatment: Inhibition by Ribavirin of possible resistant quasispecies" Lake-Bakaar, G.; Ruffini, L.; and Kuzmic, P. (2000) Digest. Dis. Week , San Diego, May 22-25, 2000. [http://www.biokin.com/virafit/papers/ddw105418.html] _____________________________________________________________________ Petr Kuzmic, Ph.D. * BioKin, Ltd. * Consulting & Software Development http://www.biokin.com * (608) 256-4790 * (608) 256-1269 FAX .